NewsPronto

 
Men's Weekly

.

ACN Newswire

Read more press releases from ACN Newswire here

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

  • Written by ACN Newswire

image

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of...

Read more: Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA...